Stop parsing PDFs. Get the API. Request Access

AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Fresenius Medical Care AG & Co. KGaA

Investor Presentation • Aug 2, 2007

165_ip_2007-08-02_ab110b73-4971-4bb7-969b-43e642ab5fa3.pdf

Investor Presentation

Open in Viewer

Opens in native device viewer

The World's Leading Renal Therapy Company

Conference Call, 2nd Quarter / 1st Half 2007 Results, August 2, 2007

© Fresenius Medical Care AG & Co. KGaA

Safe Harbor Statement

This presentation includes certain forward-looking statements. Actual results could differ materially from those included in the forwardlooking statements due to various risk factors and uncertainties, including changes in business, economic competitive conditions, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings and the availability of financing. These and other risks and uncertainties are detailed in the Company's reports filed with the Securities and Exchange Commission and the German Exchange Commission "Deutsche Börse".

Agenda

1.) I. Business Update

II. Financials Q2 and Outlook 2007

III. Q&A Session

3

Business Update

* including clinics where FME has in interest of at least 10% the amount of patients treated would be 10,994 patients in 144 clinics

Q2 2007 – Very Strong Quarter

R
e
e
n
e
v
u		 \$
2
4
0
4
m
,		 %
1
1
+
N
i
t
e
n
c
o
m
e
(
)
lu
d
in
t
im
i
te
in
2
0
0
6
ex
c
g
on
e-
e
m
s		 \$
1
9
7
m		 3
0
%
+
E
i
h
a
r
n
n
g
s
p
e
r
s
a
r
e
(
lu
d
in
t
im
i
te
in
2
0
0
6
)
ex
c
g
on
e-
e
m
s		 \$
0
6
0		 3
0
%
+

¾Continued strong development across all segments and regions

¾Continued momentum based on strong organic revenue growth of 8%

Upgrade FY 2007 guidance

Q2 2007 – Very Strong Revenue Growth in All Regions

* 9% growth at constant currency (cc)

Global – Dialysis Services

Strong revenue growth across the regions

\$
i
i
l
l
i
n
m
o
n
s		 Q
2
2
0
0
6		 Q
2
2
0
0
7		 G
t
h
r
o
w
N
h
A
i
t
o
r
m
e
r
c
a		 1
4
2
8
,		 1
4
9
9
,		 6
%
Ad
jus
ted
fo
r P
erf
ion
us
Bu
sin
ess
I
t
t
i
l
n
e
r
n
a
o
n
a		 2
2
4		 2
9
6		 3
2
%
(
2
4
%
)
c
c
T
l
t
o
a		 1
6
2
5
,		 1
9
6
7
,		 9
%
(
8
%
)
c
c

cc = constant currency

7

Global – Dialysis Services

O
i
h
f
%
i
D
i
l
i
S
i
t
7
r
g
a
n
c
r
e
v
e
n
u
e
g
r
o
w
o
n
a
y
s
s
e
r
v
c
e
s
T
t
l
o
a		 N
t
h
A
i
o
r
m
e
r
c
a		 I
t
t
i
l
n
e
r
n
a
o
n
a
%
7
+
c
c		 6
%
+		 1
3
%
+
c
c
1
%
4
+		 2
8
%
+		 3
%
7
+
1)
\$
3
2
3		 \$
1
4
9
3
%
+		 6
%
+
c
c
6
6		 4
6		 2
0
%
7
+		 %
3
+		 %
1
7
+

1) including Mexico cc=constant currency

United States – Dialysis Services

Global – Dialysis Services Quality

Fresenius Medical Care Quality Outcomes – Continued Improvement

N
t
h
A
i
o
r
m
e
r
c
a
(
%
f a
l
l
F
M
E
ien
)
t
ts
o
p
a		 E
M
i
d
d
l
E
A
f
i
t,
u
r
o
p
e
e
a
s
r
c
a
,
(
%
f a
l
l
F
M
E
t
ien
ts
)
o
p
a
Q
2
2
0
0
6		 Q
2
2
0
0
7		 Q
2
2
0
0		 Q
6
2
2
0
0
7
K
/
V
1
2
t
≥		 9
4
%		 9
4
%		 K
/
V
1
t
≥		 2 9
3		 %
9
3
%
H
l
b
i
1
1
/
d
l
≥
e
m
o
g
o
n
g		 8
1
%		 8
1
%		 H
l
e
m
o
g
o		 b
i
1
1
≥
n
g		 /
d
l
6
6		 %
2
%
7
A
l
b
i
3
/
d
l
5
≥
u
m
n
g		 8
0
%		 9
%
7		 A
l
b
i
u
m
n		 3
/
5
d
l
≥
g		 8
8		 %
8
6
%
H
i
l
i
i
d
t
t
o
s
p
a
z
a
o
n
a
y
s		 1
1
5		 1
1
2		 H
i
t
l
i
o
s
p
a		 t
i
d
z
a
o
n
a
y		 8
s		 3
8
1
N
h
A
i
(
l
l
P
i
)
t
t
t
o
r
m
e
r
c
a
a
a
e
n
s		 2
0
0
3		 2
0
0
4		 2
0
0
5		 2
0
0
6		 Q
1
2
0
0
7		 Q
2
2
0
0
7
H
i
l
i
i
D
t
t
o
s
p
a
z
a
o
n
a
y
s		 1
3.
4		 1
3.
2		 1
1.
9		 1
1.
7		 1
1.
4		 1
1.
2

10

United States – Dialysis Services Quality

Data Source: Clinical Performance Management (CPM) Data / Legacy FMC U.S. clinics

11

Global - Dialysis Products

Ongoing excellent growth

\$
i
i
l
l
i
n
m
o
n
s		 Q
2
2
0
0
6		 Q
2
2
0
0
7		 G
t
h
r
o
w
T
l
t
o
a
r
e
e
n
e
v
u		 6
7
9		 7
9
9		 1
8
%
(
i
l.
I
t
l
)
n
c
n
e
r
n
a
r
e
v
e
n
u
e		 (
1
3
%
)
c
c
E
l
t
x
e
r
n
a
r
e
v
e
n
u
e		 5
1
4		 6
0
8		 %
1
8
(
%
)
1
3
c
c
N
h
A
i
t
o
r
m
e
r
c
a		 1
3
3		 1
6
1		 2
1
%
I
i
l
t
t
n
e
r
n
a
o
n
a		 3
8
1		 4
4
7		 %
1
7
(
%
)
1
0
c
c

cc = constant currency

Region - North America

Highlights

  • ¾Ongoing strong product business
  • ¾ Revenue in dialysis services stable in Q2 despite EPO discussion
  • Still expect the underlying Rev./tmt to increase
  • Very strong cost containment led to strong margin improvement
  • ¾PhosLo sales fully in line with expectations
  • ¾Divestment of Perfusion Business Unit

Region - North America

Legislative / Regulatory Actions

  • ¾Active dialogue with FDA and CMS to ensure best patient outcomes
  • ¾ Active dialogue with U.S. legislators (both House and Senate) on medically appropriate care for ESRD patients
  • ¾ Actively promoting Kidney Care Quality bill with 12 month MSP extension recommendation
  • ¾Discussing implementation of bundle model

Region - Europe

Highlights

  • ¾Revenues will exceed \$ 2,000,000,000 in 2007
  • ¾Organic Revenue Growth of 9%
  • ¾First time achieving more than 1,000,000 treatments a quarter (+ 8%)
  • ¾Product sales growing with 9% cc
  • ¾5008 Hemodialysis Machine unit sales up 109%
  • ¾Reimbursement increases in Italy, Spain, France in H1 2007
  • ¾Sustained high profitability

cc = constant currency

Region - Europe

Patients Growth Estimates 2007 – 2012 (in Thsd.)

C
A
G
R
0<br>0<br>0
6
-		 C
A
G
R
0<br>6<br>1
2
-
E
M
i
d
d
l
E
A
f
i
t,
u
r
o
p
e,
e
a
s
r
c
a		 6.
6
%		 5.
9
%

Data Source: Company Estimates

Region – Europe

FME Target: More than \$ 1 billion in service revenues by 2010

M
i
d
2
0
0
7		 T
2
0
1
0
t
a
r
g
e
\$
7
0
0
i
l
l
i
m
o
n
~		 \$
1
1
0
0
i
l
l
i
m
o
n
~
,
3
5
3
t
c
e
n
e
r
s		 5
0
0
t
>
c
e
n
e
r
s
2
6
0
0
0
t
i
t
p
a
e
n
s
~
,		 4
0
0
0
0
t
i
t
>
p
a
e
n
s
,
1
i
7
t
c
o
n
r
e
s
u		 2
i
5
t
c
o
n
r
e
s
u
~

¾ We expect some European countries to fundamentally change their Dialysis Reimbursement System towards a Bundled Rate and combine it with advanced quality control systems (e.g. combination of quality indicators and quality objectives)

Region - Asia-Pacific

Highlights

¾Revenue will exceed \$500 million in 2007

¾Organic revenue growth of 12%cc for H1 2007

¾First time achieving more than 300,000 treatments a quarter

¾Successful integration of recent acquisitions in Taiwan and Korea

¾Japanese production sites performing well

¾Acquisition of production plant in China

-Platform for further expansion for Mainland China

cc = constant currency

Region - Asia-Pacific

Note: Myanmar, Brunei, East Timor, Papua New G, Nepal, Bangladesh, Sri Lanka, Maldives, Bhutan, Cambodia are excluded from the projection starting year 2007 (representing less than 0.5% of total Asia Pacific in 2006)

Source: Fresenius Medical Care

Summary

  • ¾Strong second quarter
  • ¾Products sales continues to grow double digit
  • ¾Expansion opportunities for Services in Europe & Asia
  • ¾Active role in legislative / regulatory issues in North America
  • ¾Upgrading our full year guidance

Financials

Profit & Loss

\$
i
i
l
l
i
n
m
o
n
s		 2)
Q
2
2
0
0
6		 Q
2
2
0
0
7		 %
N
t
e
r
e
v
e
n
u
e		 2
1
6
5
,		 2
4
0
4
,		 *
1
1
+
1)
O
i
i
(
E
B
I
T
)
t
p
e
r
a
n
g
n
c
o
m
e		 3
3
7		 3
9
1		 1
6
+
E
B
I
T
i
i
%
m
a
r
g
n
n		 1
5
5		 1
6
3
I
t
t
t
n
e
r
e
s
e
x
p
e
n
s
e
n
e
,		 1
0
0		 9
2
1)
I
b
f
i
t
n
c
o
m
e
e
o
r
e
n
c
o
m
e
a
x		 2
3
7		 2
9
9		 2
6
+
T
1)
a
x
e
x
p
e
n
s
e		 9
5		 1
1
3
T
t
a
r
a
e
x		 4
0
%		 3
8
%
M
i
i
i
t
t
t
n
o
r
y
n
e
r
e
s		 5 7
1)
N
i
t
e
n
c
o
m
e		 1
3
7		 1
7
9		 3
0
+

* 9% growth at constant currency, 8% organic growth

A reconciliation to the most directly comparable US-GAAP financial measure is provided in the attachment. 1)

Excluding one-time items 2)

EBIT margin

* Excluding one-time items

23

EBIT margin *

* Excluding one-time items. A reconciliation to the most directly comparable US-GAAP financial measure is provided in the attachment.

24

Days Sales Outstanding (DSO) – Best in Industry

© Fresenius Medical Care AG & Co. KGaA

Cash Flow

\$
i
i
l
l
i
n
m
o
n
s		 Q
2
2
0
0
6		 Q
2
2
0
0
7		 %
N
h
i
d
d
b
i
i
i
i
t
t
t
t
e
c
a
s
p
r
o
e
o
p
e
r
a
n
g
a
c
e
s
v
y
v
C
G
E
l.
R
i
i
t
i
c
a
c
q
s
o
n
x
u		 1)
2
4
0		 2
2
5
%
f r
9.
4
o
ev
en
ue		 (
)
6
2)
C
i
t
l
d
i
t
(
t
)
a
p
a
e
x
p
e
n
u
r
e
s
n
e		 (
9
)
5		 (
)
1
3
2
C
F
h
F
l
r
e
e
a
s
o
w		 1
4
5		 9
3		 (
3
6
)
A
i
i
i
t
(
l
d
i
R
C
G
i
2
0
0
6
)
c
q
s
o
n
s
u
e
x
c
u
n
g
n		 (
2
4
)		 (
2
4
)
F
C
h
F
l
(
f
i
i
i
l.
R
C
G
i
2
0
0
6
)
r
e
e
a
s
o
t
t
w
a
e
r
a
c
q
u
s
o
n
s
e
x
c
n		 1
2
1		 6
9

Excl. net tax payments of \$ 75 m and \$ 14 m payment related to the RCG acquisition 1)

A reconciliation to the most directly comparable US-GAAP financial measure is provided in the attachment. 2)

Cash Flow

\$
i
i
l
l
i
n
m
o
n
s		 1
2
0
0
6
H		 1
2
0
0
H
7		 %
N
h
i
d
d
b
i
i
i
i
t
t
t
t
e
c
a
s
p
r
o
e
o
p
e
r
a
n
g
a
c
e
s
v
y
v
C
G
E
l.
R
i
i
t
i
c
a
c
q
s
o
n
x
u		 1)
4
0
2		 0
8
5
%
f r
1
0.
7
o
ev
en
ue		 2
6
2)
C
i
t
l
d
i
t
(
t
)
a
p
a
e
x
p
e
n
u
r
e
s
n
e		 (
1
6
0
)		 (
)
2
4
0
C
F
h
F
l
r
e
e
a
s
o
w		 2
2
4		 2
6
8		 1
1
A
i
i
i
t
(
l
d
i
R
C
G
i
2
0
0
6
)
c
q
s
o
n
s
u
e
x
c
u
n
g
n		 (
3
5
)		 (
1
1
4
)
F
C
h
F
l
(
f
i
i
i
l.
R
C
G
i
2
0
0
6
)
r
e
e
a
s
o
t
t
w
a
e
r
a
c
q
u
s
o
n
s
e
x
c
n		 2
0
7		 1
5
4

Excl. net tax payments of \$ 75 m and \$ 14 m payment related to the RCG acquisition 1)

A reconciliation to the most directly comparable US-GAAP financial measure is provided in the attachment. 2)

Debt / EBITDA Development

pf = pro forma ltm = last twelve months cl = closing RCG

including non-cash charges and excluding restructuring costs, in-process R&D and gain from the sale of dialysis clinics 1)

Continued Strong Earnings per Share Growth

* Adjusted for special charge and related expenses

Outlook 2007 – Guidance Upgraded

O
l
d
G
i
d
u
a
n
c
e		 N
E
W
G
i
d
u
a
n
c
e
N
t
e
r
e
v
e
n
u
e		 \$
9
4
b
n
~		 \$
9
5
b
>
n
N
t
i
e
n
c
o
m
e		 \$
6
7
5
6
9
5
m
-		 \$
6
8
5
7
0
5
m
-
L
i
t
(
D
b
/
E
B
I
T
D
A
)
t
e
v
e
r
a
g
e
r
a
o
e		 3
0
<		 3
0
<
C
E
d
i
i
t
i
a
p
a
n
a
c
q
s
o
n
s
x
u		 \$
6
0
5
m
~		 \$
6
5
0
m
~

Thank Youfor your interest in Fresenius Medical Care !

The World's Leading Renal Therapy Company

Conference Call, 2nd Quarter / 1st Half 2007 Results, August 2, 2007

© Fresenius Medical Care AG & Co. KGaA

Attachment I

Reconciliation of non US-GAAP financial measures to the most directly comparable US-GAAP financial measure

All numbers are in \$ millions

D
b
t
e		 Q
2
2
0
0
7		 F
Y
2
0
0
6		 F
Y
2
0
0
5		 F
Y
2
0
0
4		 F
Y
2
0
0
3
1)
S
ho
bo
ing
(
inc
l.
A
/
R
)
t
te
r
rm
rro
s
p
ro
g
ra
m
w		 4
6
7		 3
3
1		 1
5
1		 4
1
9		 9
0
S
fro
ho
t
te
bo
ing
la
te
d
t
ies
+
r
rm
rro
w
s
m
re
p
ar		 2
9		 5 1
9		 6 3
0
Cu
ion
f
lon
de
b
d c
i
l
lea
b
l
ig
ion
t p
t
te
t a
ta
t
+
rre
n
or
o
g-
rm
n
ap
se
o
a
s		 1
3
5		 1
6
0		 1
2
6		 2
3
0		 9
0
Cu
t p
t
ion
f
Tr
t
Pr
fe
d
Se
i
t
ies
+
rre
n
or
o
us
e
rre
cu
r		 6
4
5
Lo
de
b
d c
i
l
lea
b
l
ig
ion
les
ion
-te
t a
ta
t
t p
t
+
ng
rm
n
ap
se
o
a
s,
s c
ur
re
n
or		 3,
7
4
1		 3,
8
2
9		 7
0
7		 5
4
5		 1,
1
1
2
fe
Se
(
f c
)
Tr
t
Pr
d
i
t
ies
t o
t p
t
ion
+
us
e
rre
cu
r
ne
ur
re
n
or		 6
2
7		 1,
2
5
4		 1,
1
8
8		 1,
2
7
9		 1,
2
4
2
Ac
ts
iva
b
le
i
t
iza
t
ion
+
co
un
re
ce
se
cu
r
p
ro
g
ra
m		 0 0 0 0 1
5
8
To
ta
l
de
b
t
=		 5,
6
6
2		 5,
5
7
9		 2,
1
9
1		 2,
4
7
9		 2,
7
2
2
E
B
I
T
D
A		 2)
Q
2
2
0
0
7		 2)
F
Y
2
0
0
6
(
fo
)
p
ro
rm
a		 F
Y
2
0
0
5		 F
Y
2
0
0
4		 F
Y
2
0
0
3
La
t
tw
lve
t
hs
t
ing
inc
(
E
B
I
T
)
s
e
m
on
o
p
er
a
om
e		 1,
4
9
0		 1,
3
6
7		 9
3
9		 8
5
2		 7
5
7
La
t
tw
lve
t
hs
de
ia
t
ion
d a
t
iza
t
ion
+
s
e
m
on
p
re
c
a
n
mo
r		 3
3
8		 3
2
6		 2
5
1		 2
3
3		 2
1
6
No
h c
ha
+
n-
ca
s
rg
es		 3
9		 3
5		 1
4		 1
3		 1
3
E
B
I
T
D
A
(
l
ize
d
)
=
an
nu
a		 1,
8
6
7		 1,
7
2
8		 1,
2
0
4		 1,
0
9
8		 9
8
6

A/R securitization program off-balance sheet in 2003 and included in short term borrowings in 2004 1)

Excluding gain from divestitures, restructuring costs and in-process R&D 2)

Attachment II

All numbers are in \$ millions

Reconciliation of non US-GAAP financial measures to the most directly comparable US-GAAP financial measure

E
l
R
t
x
e
r
n
a
e
v
e
n
u
e		 Q
2
2
0
0
7		 Q
2
2
0
0
6		 t
h
g
ro
w		 cc
In
io
l
du
te
t
t r
rn
a
na
p
ro
c
ev
en
ue		 0
8
5		 4
3
2		 1
8
%
+		 1
0
%
+
In
te
l re
rn
a
ve
nu
e
-		 (
6
1
)		 (
5
1
)
Ex
te
l r
=
rn
a
ev
en
ue		 4
4
7		 3
8
1		 %
2
0
+		 %
1
2
+
No
h
Am
ica
du
t
t r
r
er
p
ro
c
ev
en
ue		 2
9		 1
2
4
7		 1
8
%
+
In
te
l re
rn
a
ve
nu
e
-		 (
1
3
0
)		 (
1
1
4
)
Ex
te
l r
=
rn
a
ev
en
ue		 1
6		 1
1
3
3		 %
2
1
+
T
O
T
A
L
du
t r
p
ro
c
ev
en
ue		 7
9		 9
6
7
9		 9
%
+		 8
%
+
In
te
l re
rn
a
ve
nu
e
-		 (
1
9
1
)		 (
1
6
5
)
Ex
te
l r
=
rn
a
ev
en
ue		 6
0		 8
5
1
4		 %
1
8
+		 %
1
3
+
C
i
t
l
d
i
t
(
t
)
a
p
a
e
x
p
e
n
u
r
e
n
e		 H
1
2
0
0
7		 Q
2
2
0
0
7		 Q
2
2
0
0
6		 H
1
2
0
0
6
Pu
ha
f p
lan
d e
ip
ty,
t a
t
rc
se
o
ro
p
er
p
n
q
u
me
n		 2
5
2		 1
3
5		 1
0
3		 1
7
3
Pr
ds
fro
le
f p
ty,
lan
t a
d e
ip
t
oc
ee
m
sa
o
ro
p
er
p
n
q
u
me
n
-		 (
1
2
)		 (
3
)		 (
8
)		 (
1
3
8
)
Ca
(
)
i
ta
l e
d
i
tu
t
=
p
xp
en
re
ne		 2
4
0		 1
3
2		 9
5		 1
6
0

cc = constant currency

35

Attachment III

Reconciliation of non US-GAAP financial measures to the most directly comparable US-GAAP financial measure

A
l		 l n
um		 be
rs		 a
re		 in \$ i
l
m		 l
io
ns
-- -------- ----------- ---------- --------- ---- ---- ------------- ---------------
E
B
I
T
i
m
a
r
g
n
s		 Q
1
2
0
0
5		 Q
2
2
0
0
5		 Q
3
2
0
0
5		 Q
4
2
0
0
5		 F
Y
2
0
0
5
Re
ve
nu
e		 1,
6
0
9		 1,
6
7
4		 1,
7
1
7		 1,
7
7
2		 6,
7
7
2
E
B
I
T		 2
2
0		 2
3
8		 2
3
7		 2
4
4		 9
3
9
E
B
I
T
ins
m
ar
g		 1
3.
%
7		 1
4.
2
%		 1
3.
8
%		 1
3.
8
%		 1
3.
9
%
On
t
im
f
fe
ts
e-
e e
c		 1.
2		 6.
8		 1
4.
4		 2
2.
4
E
B
I
T
ins
l. o
-t
im
f
fec
ts
m
ar
g
ex
c
ne
e e		 %
1
3.
7		 %
1
4.
3		 %
1
4.
2		 %
1
4.
6		 %
1
4.
2
E
B
I
T
i
m
a
r
g
n
s		 Q
1
2
0
0
6		 Q
2
2
0
0
6		 Q
3
2
0
0
6		 Q
4
2
0
0
6		 F
Y
2
0
0
6
Re
ve
nu
e		 1,
7
4
7		 2,
1
6
5		 2,
2
3
4		 2,
3
5
2		 8,
4
9
9
E
B
I
T		 2
4
4		 3
2
7		 3
4
9		 3
4
5		 1,
3
1
8
E
B
I
T
ins
m
ar
g		 1
4.
0
%		 1
7.
2
%		 1
5.
6
%		 1
5.
0
%		 1
5.
5
%
On
t
im
f
fe
ts
e-
e e
c		 0.
4		 (
3
5.
2
)		 6 2
5.
5		 1
0.
9
E
B
I
T
ins
l. o
-t
im
f
fec
ts
m
ar
g
ex
c
ne
e e		 1
4.
0
%		 1
%
5.
5		 1
9
%
5.		 1
6.
1
%		 1
6
%
5.

Attachment IV

Reconciliation of non US-GAAP financial measures to the most directly comparable US-GAAP financial measure

\$
A
l
l n
be
in
i
l
l
io
um
rs
a
re
m
ns
O
i
f
b
f
i
i
t
t
t
p
e
r
a
n
g
p
e
r
o
r
m
a
n
c
e
e
o
r
e
o
n
e-
m
e
e
m
s		 Q
2
2
0
0
7		 Q
2
2
0
0
6		 t
h
g
ro
w
Op
(
)
t
in
in
E
B
I
T
er
a
g
co
m
e		 3
9
1		 3
7
2		 %
5
Tr
fo
ion
in
fro
d
ive
i
ing
t
t
tu
tru
tu
+
+
an
s
rm
a
g
a
m
s
re
re
s
c
r		 0 (
3
)
5
Op
in
in
(
E
B
I
T
)
be
fo
im
i
t
-t
te
er
a
g
co
m
e
re
o
ne
e-
m
s		 3
9
1		 3
3
7		 1
6
%
Ne
t
in
co
m
e		 1
7
9		 1
2
9		 3
8
%
Lo
fro
d
ive
t
i
tu
tru
tu
ing
tra
fo
t
ion
ts
+
ss
m
s
re
re
s
c
r
ns
rm
a
co
s
,		 0 8
Ne
t
in
be
fo
-t
im
i
te
co
m
e
re
o
ne
e-
m
s		 1
7
9		 1
3
7		 3
0
%
P
f
i
&
L
A
t
t
r
o
o
s
s
c
c
o
u
n		 Q
2
2
0
0
6		 On
t
im
i
te
e-
e
m
s		 Q
2
2
0
0
6
lu
d
in
im
i
t
te
ex
c
g
on
e-
e
m
s
Ne
t r
ev
en
ue		 2,
1
6
5		 2,
1
6
5
Op
(
)
t
ing
inc
E
B
I
T
er
a
om
e		 3
7
2		 (
)
3
5		 3
3
7
E
B
I
T-
in
(
%
)
m
ar
g		 1
2
7.		 1
5.
5
In
te
t e
t
re
s
xp
en
se
ne
,		 (
1
0
0
)		 (
0
)		 (
1
0
0
)
Inc
be
fo
inc
tax
om
e
re
om
e
es		 2
7
2		 2
3
7
Ta
x e
xp
en
se		 (
)
1
3
8		 4
3		 (
)
9
5
Ta
(
%
)
te
x r
a		 0.
6
5		 4
0.
1
M
ino
i
ty
in
te
t
r
re
s		 (
5
)		 (
5
)
Ne
t
in
co
m
e		 1
2
9		 8 1
3
7

Contacts

Fresenius Medical Care AG & Co. KGaAInvestor RelationsElse Kröner Str. 161352 Bad Homburg v.d.H.

Oliver MaierHead of Investor Relations & Corporate Communications Tel.: +49-(0)6172-609-2601 Fax.: +49-(0)6172-609-2301 Mob.: +49-(0)173-6522-712 Mail: [email protected]

North America:Terry L. Proveaux Tel.: +1-800-948-2538Fax.: +1-615-345-5605Mob.: +1-615-618-2987 bbMail: [email protected]

Ordinary shares

WKN 578 580ISIN DE0005785802SEDOL1 5129074 DE

ReminderReminder…..

For recent updates, please have a look at our webpage. Navigation around

www.fmc-ag.com

CalendarInvestor Relations > Financial Calendar

Annual Report / Quarterly Filings / SEC Filings / Deutsche Börse Filings …. Investor Relations > Publications

Corporate Governance / Sarbanes-Oxley Act / NYSE declaration …. Investor Relations > Corporate Governance

Financing / Analyst Coverage / Consensus estimates / Share data …. Investor Relations > Our share

More from Fresenius Medical Care AG & Co. KGaA

Declaration of Voting Results & Voting Rights Announcements 2026
Jan 16
Share Issue/Capital Change 2026
Jan 12
Transaction in Own Shares 2026
Jan 9
Share Issue/Capital Change 2025
Dec 29
AGM Information 2025
Dec 22
Declaration of Voting Results & Voting Rights Announcements 2025
Dec 15
Declaration of Voting Results & Voting Rights Announcements 2025
Dec 12
Declaration of Voting Results & Voting Rights Announcements 2025
Dec 8
Declaration of Voting Results & Voting Rights Announcements 2025
Dec 3
Transaction in Own Shares 2025
Dec 1
View all filings →

Talk to a Data Expert

Have a question? We'll get back to you promptly.